Document:

Exhibit 4.3

 

Consent of Independent Registered
Public Accounting Firm

We consent to the
reference made to our firm under the caption “Independent Registered Public Accounting Firm” in Part B of the Prospectus
and to the use of our report dated November 1, 2016, in this Registration Statement (Form S-6 No. 333-213458) of Smart Trust 277,
comprising Smart Trust, Zacks GARP Composite 35 Trust, Series 11.

 

/s/ Grant
Thornton LLP

 

Chicago, Illinois

November 1, 2016EX-4.1

 Exhibit 4.1 

EXECUTION VERSION 
 FIRST
SUPPLEMENTAL INDENTURE 
 dated as of October 31, 2016 

by and among 
 Monster Worldwide,
Inc., 
 and 
 Wilmington Trust,
National Association, 
 as Trustee 
  

 
 3.50%
Convertible Senior Notes due 2019 

 THIS FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”),
entered into as of October 31, 2016, by and between Monster Worldwide, Inc., a Delaware corporation (the “Company”), and Wilmington Trust, National Association, as trustee (the “Trustee”), supplements and
amends the Indenture (as defined herein). 
 RECITALS 

WHEREAS, the Company and the Trustee heretofore entered into that certain Indenture, dated as of October 22, 2014 (the
“Indenture”), pursuant to which the Company’s 3.50% Convertible Senior Notes due 2019 (the “Notes”) were issued; 

WHEREAS, the Company, Randstad North America, Inc., a Delaware corporation (“Parent”), and Merlin Global Acquisition,
Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), are parties to that certain Agreement and Plan of Merger dated as of August 8, 2016 (the “Merger Agreement”), pursuant to
which, Merger Sub agreed to commence a tender offer to acquire all of the outstanding shares of common stock of the Company for $3.40 per share in cash, without interest thereon and less any applicable withholding taxes (the “Acquisition
Offer Consideration”); 
 WHEREAS, at the effective time of the Acquisition (the “Effective Time”),
Merger Sub will be merged with and into the Company with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the “Acquisition”), and each share of common stock of the Company issued and
outstanding immediately prior to the Effective Time will be converted into the right to receive the Acquisition Offer Consideration, as set forth in the Merger Agreement; 

WHEREAS, Section 14.07(a) of the Indenture provides that in the case of any consolidation, merger, combination or similar
transaction involving the Company, as a result of which the common stock of the Company would be converted into, or exchanged for, stock, other securities, other property or assets (including cash or any combination thereof) (such event, a
“Merger Event”), then, at and after the Effective Time, the right to convert such $1,000 principal amount of Notes shall be changed into the right to convert such principal amount of Notes into the kind and amount of shares of
stock, other securities or other property or assets (including cash or any combination thereof) that a holder of a number of shares of common stock of the Company equal to the Conversion Rate immediately prior to such Merger Event would have owned
or been entitled to receive (the “Reference Property,” with each “unit of Reference Property” meaning the kind and amount of Reference Property that a holder of one share of common stock of the Company is entitled
to receive) upon such Merger Event; 

  
 1 

 WHEREAS, Section 14.07(a) of the Indenture also provides that prior to or at the Effective
Time of the Merger Event, the Company shall execute with the Trustee a supplemental indenture permitted under Section 10.01(g) of the Indenture providing for the change in the right to convert each $1,000 principal amount of Notes; 

WHEREAS, Section 10.01(g) of the Indenture provides that the Company and the Trustee may modify or amend the Indenture without the
consent of the Holders in connection with any Merger Event to provide that the Notes are convertible into cash and Reference Property (if any); 

WHEREAS, pursuant to Section 14.07(a) of the Indenture, the Company has requested the Trustee to execute this Supplemental Indenture to
evidence that Notes are convertible into the Acquisition Offer Consideration; 
 WHEREAS, the Company has delivered to the Trustee an
Officers’ Certificate and Opinion of Counsel, each complying with Sections 10.05 and 17.05 of the Indenture; and 
 WHEREAS, all acts
and requirements necessary to make this Supplemental Indenture a legal, valid and binding agreement of the Company have been done. 

AGREEMENT 
 NOW,
THEREFORE, in consideration of the premises and mutual covenants herein contained and intending to be legally bound, the parties to this Supplemental Indenture hereby agree as follows: 

Section 1. Capitalized terms used herein and not otherwise defined herein are used as defined in the Indentures. 

Section 2. In accordance with Section 14.07(a)(ii) of the Indenture, each $1,000 principal amount of Notes shall be
convertible into the Acquisition Offer Consideration receivable by a holder of a number of shares of common stock of the Company that would have been issuable upon conversion of such principal amount of Notes immediately prior to the Acquisition
(i.e., the right to convert each $1,000 principal amount of Notes shall be changed into a right to convert such principal amount into cash in an amount equal to $638.3177). 

Section 3. This Supplemental Indenture shall be governed by and construed in accordance with the laws of the State of New York.

 Section 4. This Supplemental Indenture may be signed in various counterparts which together will constitute one and the
same instrument. 

  
 2 

 Section 5. This Supplemental Indenture is an amendment supplemental to the Indenture,
and the Indenture and this Supplemental Indenture will henceforth be read together. 
 Section 6. The Trustee shall not
be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Company. 

Section 7. The provisions of this Supplemental Indenture shall be effective only upon execution and delivery of this instrument by
the parties hereto. Notwithstanding the foregoing sentence, the provisions of this Supplemental Indenture shall become operative only upon the closing of the Acquisition, with the result that the amendments to the Indenture effected by this
Supplemental Indenture shall be deemed to be revoked retroactive to the date hereof if such closing shall not occur. The Company shall notify the Trustee promptly after the occurrence of such closing or promptly after the Company shall determine
that such closing will not occur. 
 [Signature pages follow] 

  
 3 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the date first above written. 
  

					
	Monster Worldwide, Inc.
		
	By:	 	   /s/ Timothy T. Yates

		 	Name:	 	Timothy T. Yates
		 	Title:	 	Chief Executive Officer and Chief Financial Officer
	
	 Wilmington Trust, National Association

    as Trustee

		
	By:	 	   /s/ Lynn M. Steiner

		 	Name:	 	Lynn M. Steiner
		 	Title:	 	Vice President

 [Signature Page to First Supplemental Indenture]ex10-1.htm

EXHIBIT 10.1

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL

SECOND AMENDMENT TO SUPPLY AND RESELLER AGREEMENT

 

This Second Amendment (“Second Amendment”) to the Supply and Reseller Agreement dated August 12, 2013, is made this 26th day of July, 2016 (“Second Amendment Effective Date”), by and between LIFE TECHNOLOGIES CORPORATION, a Delaware corporation, that is a wholly-owned subsidiary Thermo Fisher Scientific, Inc., with a principal business address at 29851 Willow Creek Road, Eugene, Oregon 97402, USA (“LTC”) and OXFORD IMMUNOTEC, LTD., a company incorporated under the laws of England and Wales, with a principal business address at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, United Kingdom (“OI”). LTC and OI may be referred to individually as a “Party” and collectively as the “Parties.”

 

WHEREAS, LTC and OI entered into a Supply and Reseller Agreement effective August 12, 2013, which was amended on March 1, 2014 (collectively, the “AGREEMENT”); and

 

WHEREAS, the Parties have agreed to extend the expiration date of the AGREEMENT until December 31, 2018 and to establish the purchase price for LTC PRODUCTS for the remaining duration of the AGREEMENT; and 

 

WHEREAS, the Parties have agreed that the LTC PRODUCT will bear a revised label indicating that it has been manufactured by LTC for OI; and 

 

WHEREAS, the Parties have agreed to update LTC’s information for notices under the AGREEMENT;

 

NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties intending to be legally bound agree as follows:

 

1.0     Amendment

Numbered paragraph 2.9 of the AGREEMENT shall be deleted in its entirety and replaced with the following paragraph:

 

2.9     “FIELD OF USE” means use related to the performance of ELISPOT assays for human in vitro diagnostic applications.

 

	
Oxford Immunotec Second Amendment to 

Supply and Reseller Agreement

460508
	
Page 1 of 9

 

 

 

 

 

EXHIBIT 10.1

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL

2.0     Amendment

 

Numbered paragraph 2.13 of the AGREEMENT shall be deleted in its entirety and replaced with the following paragraph:

 

2.13     “OI TESTING SERVICE” means use of LTC PRODUCT(S) or OI PRODUCT(S) to perform an ELISPOT test for fee consideration by or on behalf of OI.     

 

3.0     Amendment

 

Clause (d) of numbered paragraph 3.2 of the AGREEMENT shall be deleted in its entirety and replaced with the following clause:

 

(d) OI’s or its AFFILIATES’ internal research and development relating to OI PRODUCTS and OI TESTING SERVICES.

 

4.0     Amendment

 

Numbered paragraph 4.5 of the AGREEMENT shall be deleted in its entirety and replaced with the following paragraph:

 

 

OI acknowledges that LTC PRODUCTS that are commercialized by LTC and its AFFILIATES primarily as research reagents may not be on the US Toxic Substances Control Act (TSCA) inventory and are exempt from Pre-Manufacture Notification (PMN) requirements under TSCA, or similar regulations or government controls in other jurisdictions. OI shall be solely responsible for obtaining all applicable regulatory authorizations, consents and licenses, including pre-market approvals, and OI must comply and require its AFFILIATES and DISTRIBUTORS to comply with all governmental requirements, including but not limited to, all applicable laws, statutes, regulations, and treaties, relating to the manufacture, pre-marking and marketing, sale, performance, storage, shipment, and distribution of OI PRODUCTS and/or OI SERVICES by or on behalf of OI, and relating to the performance of OI’s duties and obligations under this AGREEMENT. LTC or its AFFILIATES shall provide directly to any applicable regulatory agencies any information or documentation which is reasonably requested in order for OI or its AFFILIATES to obtain and maintain certifications or regulatory approvals for the labelling, marketing, sale or distribution of the LTC PRODUCTS as contemplated by this AGREEMENT. 

 

	
Oxford Immunotec Second Amendment to 

Supply and Reseller Agreement

460508
	
Page 2 of 9

 

 

 

 

 

EXHIBIT 10.1

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL

 5.0     Amendment

 

Numbered paragraph 7.2 of the AGREEMENT shall be deleted in its entirety and replaced with the following paragraph:

 

7.2     As noted in Exhibit C (pricing of LTC PRODUCTS), the initial purchase price may be subject to a standard price increase set forth therein, which standard price increase shall be separate from, and/or in addition to any price change resulting from a change in the specifications for such LTC PRODUCT that is requested by OI pursuant to paragraph 6.3 (modified specifications), and which standard price changes shall be effective for any shipment that occurs after the date of implementation thereof.

 

6.0     Amendment

 

Numbered paragraph 16.1 is hereby deleted in its entirety and replaced with the following:

 

16.1     This AGREEMENT will commence on the EFFECTIVE DATE and, unless terminated earlier as provided herein, all obligations of LTC or its AFFILIATES to supply LTC PRODUCTS hereunder shall expire on December 31, 2018 (the “Initial Term”).

 

	
Oxford Immunotec Second Amendment to 

Supply and Reseller Agreement

460508
	
Page 3 of 9

 

 

 

 

 

EXHIBIT 10.1

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL

7.0     Amendment

 

All paragraphs in Article 17 of the AGREEMENT shall be deleted in their entirety and replaced with the following paragraphs:

 

17.1     Any notices required or permitted to be given under this AGREEMENT shall be deemed given on the date submitted in writing: (i) personally; or (ii) by a letter delivered to a courier guaranteeing next day service; or (iii) by facsimile or E-mail, with confirmation by prepaid first class letter sent the same day. 

 

If to LTC:               THERMO FISHER SCIENTIFIC

Life Technologies

5791 Van Allen Way

Carlsbad, CA 92008

USA

Attention: License Management & Contract Compliance

E-mail: LMCC@thermofisher.com

 

with a copy to:      THERMO FISHER SCIENTIFIC

Life Technologies

29851 Willow Creek Road

Eugene, OR 97402-9132

USA

Attention: Business Development Department

Facsimile: 1-541-335-0354

 

If to OI:                  OXFORD IMMUNOTEC LIMITED

94C Innovation Drive

Milton Park, Abingdon

Oxfordshire OX14 4RZUnited Kingdom

Attention: Peter Edwardson

 

With a copy to:    OXFORD IMMUNOTEC INC.

General Counsel

700 Nickerson Road

Suite 200

Marlborough, MA 01752

USA

 

	
Oxford Immunotec Second Amendment to 

Supply and Reseller Agreement

460508
	
Page 4 of 9

 

 

 

 

EXHIBIT 10.1

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL 

17.2     Any Party may change its designated address or other contact information by notice to the other Party in the manner provided in this Article.

 

 

	
8.0
	
Amendment

Exhibit A to the AGREEMENT is hereby deleted in its entirety and replaced with the attached Exhibit A.

 

	
9.0
	
Amendment

Exhibit C to the AGREEMENT is hereby deleted in its entirety and replaced with the attached Exhibit C.

 

	
10.0
	
Amendment

The Label referenced in the Specifications set forth on Exhibit D to the AGREEMENT will be in accordance with the images set forth in the attached Attachment 1, which is hereby added to Exhibit D.

 

	
11.0
	
Miscellaneous

The terms of the AGREEMENT not specifically modified by this Second Amendment shall continue in effect, and all references to the AGREEMENT hereinafter shall refer to the AGREEMENT as amended by this Second Amendment.

 

	
12.0
	
Execution by the Parties

IN WITNESS WHEREOF, the Parties have caused this Second Amendment to be executed by their duly authorized representative. This Second Amendment may be executed in one or more counterparts, each of which will be deemed an original, but all of which will constitute one and the same instrument. For purposes hereof, the Parties may sign and deliver this Second Amendment by facsimile transmission or electronic transmission in Portable Document Format ("PDF"). Each Party agrees that the delivery of this Second Amendment by facsimile or PDF will be deemed to be an original. 

 

	
Oxford Immunotec Second Amendment to 

Supply and Reseller Agreement

460508
	
Page 5 of 9

 

 

 

 

 

EXHIBIT 10.1

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL

  

	 	
LIFE TECHNOLOGIES CORPORATION
	
OXFORD IMMUNOTEC LIMITED

	 	 	 
	 	 	 
	 	By:	/s/ Rolando Brawer 	 	By:	/s/ Peter Edwardson	 
	 	Rolando Brawer                         	Peter Edwardson
	 	Director, Business Development               	Chief Operations Officer                    
	 	 	 

 

	 	Date: 	 August 9, 2016	 	Date:	1st August 2016	 

 

 

 

 

 

	
Oxford Immunotec Second Amendment to 

Supply and Reseller Agreement

460508
	
Page 6 of 9

 

 

 

 

 

EXHIBIT 10.1

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL 

Exhibit A: AUTHORIZED LTC AFFILIATES (as amended in accordance with the Second Amendment)

For the purchase of LTC PRODUCTS that will be supplied to OI or its AFFILIATES in the US, the AUTHORIZED LTC AFFILIATE is:

 

Life Technologies Corporation

A Thermo Fisher Scientific company

3175 Staley Road

Grand Island, NY 14072

USA

 

To Order:

E-mail: CustomMedia@lifetch.com 

 

For the purchase of LTC PRODUCTS that will be supplied to OI or its AFFILIATES in the UK, the AUTHORIZED LTC AFFILIATE is:

 

Life Technologies Limited

A Thermo Fisher Scientific company

3 Fountain Drive

Inchinnan Business Park

Paisley, UK

PA4 9RE 

Phone: 0044 141 814 6100

E-mail: mpinquiries-orders@lifetech.com

 

OI FACILITY

	
Oxford Immunotec Limited

94C Innovation Drive

Milton Park, Abingdon

Oxfordshire OX14 4RZ

United Kingdom
	
Oxford Immunotec, Inc. 

5846 Distribution Drive

Memphis, TN 38141

USA

 

	
Oxford Immunotec Second Amendment to 

Supply and Reseller Agreement

460508
	
Page 7 of 9

         

 

 

 

 

EXHIBIT 10.1

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL 

Exhibit C: Pricing of LTC PRODUCTS1 (as amended in accordance with the Second Amendment)

 

	
LTC PRODUCT
	
2015 Purchase Price to

OI
	
Minimum

Shipment/Minimum

Order (UNITS

per 

shipment/order) 2 
	
Standard Price 

Change

	
AIM V ® 500 mL

Package in Gibco

Boxy Bottle
	
[***]
	
[***]
	
[***]

	
AIM V® 50 mL 

Custom Pkg. 
	
[***]
	
[***]
	
[***]

1 Subject to the provisions of paragraph 4.1 (source of supply) and Article 7 (pricing)

2 as set forth in paragraph 4.3 (required minimums) of this AGREEMENT

Minimum Annual Purchase 

Beginning in 2013, OI shall purchase from the respective AUTHORIZED LTC AFFILIATE, a Minimum Annual Purchase of LTC PRODUCTS as set forth in the table at the end of this paragraph. 

 

	
YEAR
	
Minimum Annual Purchase

	
2013
	
[***]1

	
2014
	
[***]1

	
2015
	
[***]1

	
2016
	
[***]1

	
2017
	
[***]1

	
2018
	
[***]1

1 Failure to meet these Minimum Annual Purchase amounts for a given YEAR will incur a [***] percent ([***]%) increase in the price of the LTC PRODUCT for the following YEAR. For purposes of clarification, in the event OI meets or exceeds the Minimum Annual Purchase amount for a given YEAR, the price of the LTC PRODUCT for the following YEAR shall not be subject to an increase.

 

 

 

 

	
Oxford Immunotec Second Amendment to 

Supply and Reseller Agreement

460508
	
Page 8 of 9

 

 

 

 

 

EXHIBIT 10.1

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL 

Exhibit D

 

Attachment 1: Label Images

 

 

		

 

 

 

 

	
Oxford Immunotec Second Amendment to 

Supply and Reseller Agreement

460508
	
Page 9 of 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]